Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 137 Parkinson Disease 4, Autosomal Dominant Lewy Body 125 Melanoma 95 Neoplasms 75 Squamous Cell Carcinoma of Head and Neck 65 Colorectal Neoplasms 42 Triple Negative Breast Neoplasms 38 Carcinoma, Renal Cell 37 Lung Neoplasms 36 Stomach Neoplasms 35 Head and Neck Neoplasms 34 Breast Neoplasms 34 Urinary Bladder Neoplasms 32 Neoplasm Metastasis 32 Carcinoma, Hepatocellular 32 Pancreatic Neoplasms 30 Ovarian Neoplasms 29 Carcinoma, Transitional Cell 25 Endometrial Neoplasms 19 Recurrence 16 Sarcoma 15 Esophageal Neoplasms 15 Carcinoma 15 Uterine Cervical Neoplasms 14 Prostatic Neoplasms 14 Small Cell Lung Carcinoma 13 Lymphoma 13 Fallopian Tube Neoplasms 13 Carcinoma, Squamous Cell 13 Lymphoma, Non-Hodgkin 12

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Urothelial Bladder Carcinoma × pembrolizumab × Clear all

NCT02736266 2023-07-18

PURE-01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡